Author Archive for: jerry@jerry-liu.com
Entries by Jerry Liu
PCPA in the New – 24 Nov 2024
Drug Subsidy bridging fund required for cancer patients, experts argue
Posted 24 November 2024
Jacinta Frawley, a psychotherapist from Sutherland in Sydney, had a stage three ovarian cancer diagnosis that was unresponsive to treatment – until a new treatment handed her a new lease on life.
Click here to read the full article
Read more online at the Australian (Subscription required)
PCPA in the news – Oncologist face PBS drug dilemma
pharma in focus 28 Aug- 1 Sept 2023
Posted 28 August 2023
Offering innovative but costly therapies is a major dilemma faced by Australian oncologists with a new survey finding they fear putting their patients under financial stress.
The survey, conducted by Servier Laboratories, aimed to unpack the barriers to cancer clinicians offering new therapies that are not available on the PBS to their patients.
While pharmaceutical companies often step in with a level of discount, known as co-pay programs, it still means considerable out […]
PCPA in the news – New podcast urges stakeholders to speak out on access to new technologies
June 30, 2023
AstraZeneca has supported a new podcast that calls for accelerated access to innovative precision medicines and genomic profiling.The podcast is the third in the Private Cancer Physicians of Australia’s (PCPA’s) Cancer Patient Management series.
PCPA, Australia’s peak body for private cancer specialists, has joined other oncology and patient groups to advocate for removing the cost and regulatory barriers for patients with cancer accessing upfront molecular profiling.
PCPA in the news – New platform for oncologist MedEd
pharma in focus 19 June – 23 June 2023
Posted 21 June 2023
Pharma has a key role to play in helping cancer specialists meet their professional development requirements – and a new digital platform could help that partnership grow further.
The Private Cancer Physicians of Australia (PCPA) has announced the launch of a new digital platform, CPD4MedProfessional.com, which will help cancer specialists meet their updated continuing professional development (CPD) requirements.
The new online support program has been developed with the PCPA’s education partners ScienceToLife.
Currently seven pharma […]
PCPA in the news – can ‘smart bombs’ replace chemo?
pharma in focus 13 June – 16 June 2023
Posted 15 June 2023
Antibody-drug conjugates (ADCs), described as “biological missiles” and “smart bombs” against cancer, could have the potential to replace chemotherapy for metastatic breast cancer.
Speaking on the Private Cancer Physicians of Australia Podcast series, University of California San Francisco Director of Breast Oncology Professor Hope Rugo said the precise and potent surface-antibody drugs were proving effective and better tolerated than existing treatments.
“This is such an exciting topic for all of us,” Rugo said. “It pervades everything […]